Bleakley Financial Group Reduces Stake in Takeda Pharmaceutical as Company Continues Global Expansion and Innovation
On September 9, 2023, it was reported that Bleakley Financial Group LLC had reduced its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 3.4% during the first quarter of the year, according to a recent disclosure with the Securities & Exchange Commission. After selling 6,814 shares, the firm now owns 195,345 shares of the company’s stock. As of its most recent filing with the Securities & Exchange Commission, Bleakley Financial Group LLC’s holdings in Takeda Pharmaceutical were valued at $3,219,000.
Takeda Pharmaceutical (NYSE:TAK) recently released its earnings results on Thursday, July 27th. In the second quarter, it reported earnings per share (EPS) of $0.55 and generated revenue of $7.71 billion. The company’s net margin stood at 7.34%, while its return on equity was reported to be 12.54%. Market analysts predict that Takeda Pharmaceutical Company Limited will likely post EPS of $0.36 for the current fiscal year.
As an internationally renowned pharmaceutical company, Takeda Pharmaceutical engages in various aspects of the industry across multiple regions including Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and globally as well. The company focuses on research and development, manufacturing and marketing pharmaceutical products in fields such as gastroenterology, rare diseases, plasma-derived therapies immunology oncology and neuroscience.
With a diversified product portfolio and a strong presence in key global markets, Takeda Pharmaceutical continues to make significant contributions to the advancement and innovation within the pharmaceutical industry.
Takeda Pharmaceutical Company Limited
TAK
Buy
Updated on: 10/09/2023
Price Target
Show more
Social Sentiments
We did not find social sentiment data for this stock
Analyst Ratings
There are no analysts data to display
Hedge Funds and Institutional Investors Show Interest in Takeda Pharmaceutical
In recent months, hedge funds and other institutional investors have made significant changes to their positions in Takeda Pharmaceutical. Envestnet Asset Management Inc., for example, grew its position in the company by a staggering 324.8% during the first quarter of this year. The firm now owns 4,699,603 shares of Takeda’s stock valued at $19,282,000 after acquiring an additional 3,593,286 shares in the last quarter.
Similarly, Point72 Asset Management L.P. also purchased a new position in Takeda Pharmaceutical during the fourth quarter of last year. This purchase was estimated to be worth around $43,410,000. Additionally, Arrowstreet Capital Limited Partnership lifted its holdings in the company by 171.3% during the same period. The firm now owns 3,904,296 shares of Takeda’s stock valued at $60,907,000 after acquiring an additional 2,465,178 shares.
Brandes Investment Partners LP experienced remarkable growth in its holdings as well during the first quarter of this year. The firm’s ownership of Takeda Pharmaceutical increased by a staggering 1,435.2%, with Brandes Investment Partners LP now owning 1,817,972 shares valued at $29,960,000.
Lastly,Millennium Management LLC saw significant growth as well when it comes to their position in Takeda Pharmaceutical. The firm boosted its holding by an impressive 124.1% during the fourth quarter of last year and currently owns 2,238,381 shares valued at $34 ,919 million
It is important to note that hedge funds and other institutional investors own approximately 2.65% of the company’s stock.
As for TAK stock itself,the market opened on Friday at a price of $15.30.The company has had a relatively stable performance recently with a fifty-day simple moving average of $15.35 and a two-hundred-day simple moving average of $15.94. Takeda Pharmaceutical has a debt-to-equity ratio of 0.63, indicating a well-managed financial position. Furthermore, it boasts a current ratio of 0.99 which suggests that the company is able to meet its short-term liabilities comfortably.
Over the past year, Takeda Pharmaceutical’s stock price has ranged between $12.28 and $17.15, with a market capitalization of $48.42 billion.The stock currently carries a price-to-earnings ratio of 21.25 and a PEG ratio of 6.64, indicating that it may be overvalued compared to industry peers.
Several research firms have recently provided their insights on TAK stock as well. TheStreet upgraded shares of Takeda Pharmaceutical from a “d” rating to a “c” rating in May 2023, suggesting positive growth prospects for the company. Conversely, JPMorgan Chase & Co.downgraded TAK’s target price from $14.20 to $14.00 in September this year.
In conclusion, Takeda Pharmaceutical has garnered significant interest from hedge funds and institutional investors in recent times due to its attractive financial metrics and potential for growth in the pharmaceutical industry.With a stable performance observed lately,the company exhibits promising prospects for future investments.However,it is crucial for potential investors to conduct thorough research and analysis before making any investment decisions regarding Takeda Pharmaceutical’s stock.
No Byline Policy
Editorial Guidelines
Corrections Policy
Source